Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome

References

• MuckleTJWellsMUrticaria, deafness, and amyloidosis: a new heredo-familial syndromeQ J Med19623123524814476827
   PubMedGoogle Scholar
• WandererAAHoffmanHMThe spectrum of acquired and familial cold-induced urticaria/urticaria-like syndromesImmunol Allergy Clin North Am200424259286vii15120151
   PubMed Web of Science ®Google Scholar
• PrieurAMA recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathyClin Exp Rheumatol20011910310611247311
   PubMed Web of Science ®Google Scholar
• HassinkSGGoldsmithDPNeonatal onset multisystem inflammatory diseaseArthritis Rheum1983266686736847730
   PubMed Web of Science ®Google Scholar
• PrieurAMGriscelliCLampertFA chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patientsScand J Rheumatol Suppl19876657683482735
   PubMedGoogle Scholar
• CuissetLDrenthJPBerthelotJMGenetic linkage of the Muckle-Wells syndrome to chromosome 1q44Am J Hum Genet1999651054105910486324
   PubMed Web of Science ®Google Scholar
• HoffmanHMWrightFABroideDHWandererAAKolodnerRDIdentification of a locus on chromosome 1q44 for familial cold urticariaAm J Hum Genet2000661693169810741953
   PubMed Web of Science ®Google Scholar
• HoffmanHMMuellerJLBroideDHWandererAAKolodnerRDMutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndromeNat Genet20012930130511687797
   PubMed Web of Science ®Google Scholar
• FeldmannJPrieurAMQuartierPChronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytesAm J Hum Genet20027119820312032915
   PubMed Web of Science ®Google Scholar
• AksentijevichINowakMMallahMDe novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseasesArthritis Rheum2002463340334812483741
   PubMed Web of Science ®Google Scholar
• MartinonFMayorATschoppJThe inflammasomes: guardians of the bodyAnnu Rev Immunol20092722926519302040
   PubMed Web of Science ®Google Scholar
• FranchiLEigenbrodTMuñoz-PlanilloRNuñezGThe inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesisNat Immunol20091024124719221555
   PubMed Web of Science ®Google Scholar
• NevenBCallebautIPrieurAMMolecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, and FCUBlood20041032809281514630794
   PubMed Web of Science ®Google Scholar
• DinarelloCAInterleukin-1beta and the autoinflammatory diseasesN Engl J Med20093602467247019494224
   PubMed Web of Science ®Google Scholar
• ChaeJJWoodGMastersSLThe B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta productionProc Natl Acad Sci U S A20061039982998716785446
   PubMed Web of Science ®Google Scholar
• AksentijevichIMastersSLFergusonPJAn autoinflammatory disease with deficiency of the interleukin-1-receptor antagonistN Engl J Med20093602426243719494218
   PubMed Web of Science ®Google Scholar
• HawkinsPNLachmannHJMcDermottMFInterleukin-1-receptor antagonist in the Muckle-Wells syndromeN Engl J Med20033482583258412815153
   PubMed Web of Science ®Google Scholar
• HoffmanHMRosengrenSBoyleDLPrevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonistLancet20043641779178515541451
   PubMed Web of Science ®Google Scholar
• Goldbach-ManskyRDaileyNJCannaSWNeonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibitionN Engl J Med200635558159216899778
   PubMed Web of Science ®Google Scholar
• RossJBFinlaysonLAKlotzPJUse of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-upJ Cutan Med Surg20081281618258152
   PubMed Web of Science ®Google Scholar
• HawkinsPNLachmannHJAgannaEMcDermottMFSpectrum of clinical features in Muckle-Wells syndrome and response to anakinraArthritis Rheum20045060761214872505
   PubMed Web of Science ®Google Scholar
• HawkinsPNBybeeAAgannaEMcDermottMFResponse to anakinra in a de novo case of neonatal-onset multisystem inflammatory diseaseArthritis Rheum2004502708270915334488
   PubMed Web of Science ®Google Scholar
• FrenkelJWulffraatNMKuisWAnakinra in mutation-negative NOMID/CINCA syndrome: comment on the articles by Hawkins et al and Hoffman and PatelArthritis Rheum2004503738373915529342
   PubMed Web of Science ®Google Scholar
• LovellDJBowyerSLSolingerAMInterleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory diseaseArthritis Rheum2005521283128615818707
   PubMed Web of Science ®Google Scholar
• GattornoMTassiSCartaSPattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutationsArthritis Rheum2007563138314817763411
   PubMed Web of Science ®Google Scholar
• NevenBMarvilletITerradaCLong-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndromeArthritis Rheum20106225826720039428
   PubMed Web of Science ®Google Scholar
• LeporeLPaloniGCaorsiRFollow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with anakinraJ Pediatr201015731031520472245
   PubMed Web of Science ®Google Scholar
• Goldbach-ManskyRShroffSDWilsonMA pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndromeArthritis Rheum2008582432244218668591
   PubMed Web of Science ®Google Scholar
• HoffmanHMThroneMLAmarNJEfficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studiesArthritis Rheum2008582443245218668535
   PubMed Web of Science ®Google Scholar
• LachmannHJLowePFelixSDIn vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromesJ Exp Med20092061029103619364880
   PubMed Web of Science ®Google Scholar
• LachmannHJQuartierPSoAHawkinsPNThe emerging role of interleukin-1β in autoinflammatory diseasesArthritis Rheum10212010 Epub ahead of print
   Google Scholar
• LachmannHJKone-PautIKuemmerle-DeschnerJBUse of canakinumab in the cryopyrin-associated periodic syndromeN Engl J Med20093602416242519494217
   PubMed Web of Science ®Google Scholar
• SalliotCDougadosMGossecLRisk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trialsAnn Rheum Dis200968253218203761
   PubMed Web of Science ®Google Scholar
• IlowiteNPorrasOReiffAAnakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: Safety and preliminary efficacy results of a randomized multicenter studyClin Rheumatol20092812913718766426
   PubMed Web of Science ®Google Scholar
• QuartierPTaupinPBourdeautFEfficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset typeArthritis Rheum2003481093110112687553
   PubMed Web of Science ®Google Scholar
• PascualVAllantazFArceEPunaroMBanchereauJRole of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockadeJ Exp Med20052011479148615851489
   PubMed Web of Science ®Google Scholar
• AllantazFChaussabelDStichwehDBlood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockadeJ Exp Med20072042131214417724127
   PubMed Web of Science ®Google Scholar
• VerbskyJWWhiteAJEffective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritisJ Rheumatol2004312071207515468378
   PubMed Web of Science ®Google Scholar
• LequerréTQuartierPRoselliniDInterleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in FranceAnn Rheum Dis20086730230817947302
   PubMed Web of Science ®Google Scholar
• GattornoMPicciniALasiglièDThe pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritisArthritis Rheum2008581505151518438814
   PubMed Web of Science ®Google Scholar
• ZeftAHollisterRLaFleurBAnakinra for systemic juvenile arthritis: the Rocky Mountain experienceJ Clin Rheumatol20091516116419363453
   PubMed Web of Science ®Google Scholar
• NigrovicPAMannionMPrinceFHAnakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritisArthritis Rheum2010114 Epub ahead of print
   Google Scholar
• QuartierPAllantazFCimazRA multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Ann Rheum Dis12102010 Epub ahead of print
   Google Scholar
• LovellDJGianniniEHKimuraYPreliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 Inhibitor, in systemic juvenile idiopathic arthritisArthritis Rheum200756S514
   Google Scholar
• LovellDJGianniniEHKimuraYLong-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritisPresented at: European League Against Rheumatism annual scientific meetingJune 19–21 2009Mackinac Island, MI Abstr 2053
   Google Scholar
• RupertoNQuartierPWulffraatNACZ885 (canakinumab), A new IL-1 beta blocking monoclonal antibody has a beneficial effect in children with systemic juvenile idiopathic arthritisPresented at: European League against Rheumatism annual scientific meeting, 2009June 10–13 2009Copenhagen, Denmark Abstr OP-0298
   Google Scholar
• DebiaisSMaillotFLucaLBuretJFautrelBRenardJPEfficacy of anakinra in a case of refractory Still’s diseaseJ Clin Rheumatol20081435735819033875
   PubMed Web of Science ®Google Scholar
• RaffeinerBBotsiosCDinarelloCOmettoFPunziLRamondaRAdult-onset Still’s disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinraJoint Bone Spine10292010 Epub ahead of print
   Web of Science ®Google Scholar
• MitroulisIPapadopoulosVPKonstantinidisTRitisKAnakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patientNeth J Med20086648949119075317
   PubMed Web of Science ®Google Scholar
• MoserCPohlGHaslingerISuccessful treatment of familial Mediterranean fever with anakinra and outcome after renal transplantationNephrol Dial Transplant20092467667819033248
   PubMed Web of Science ®Google Scholar
• PetropoulouADRobinMSociéGGalicierLTransmission of familial Mediterranean fever mutation after bone marrow transplantation and successful treatment with anakinraTransplantation20109010210320606570
   PubMed Web of Science ®Google Scholar
• SacréKBrihayeBLidoveODramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapyJ Rheumatol20083535735818260167
   PubMed Web of Science ®Google Scholar
• GattornoMPelagattiMAMeiniAPersistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndromeArthritis Rheum2008581516152018438813
   PubMed Web of Science ®Google Scholar
• ObiciLMeiniACattaliniMFavourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosisAnn Rheum Dis12202010 Epub ahead of print
   Web of Science ®Google Scholar
• LequerréTVittecoqOPouplinSMevalonate kinase deficiency syndrome with structural damage responsive to anakinraRheumatology (Oxford)2007461860186217965046
   PubMed Web of Science ®Google Scholar
• Van der HilstJCBodarEJBarronKSLong-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndromeMedicine (Baltimore)20088730131019011501
   PubMed Web of Science ®Google Scholar
• Van der HilstJCFrenkelJHyperimmunoglobulin D syndrome in childhoodCurr Rheumatol Rep20101210110720425018
   PubMedGoogle Scholar
• SchusterCKränkeBAbererEArbabESturmGAbererWSchnitzler syndrome: response to anakinra in two cases and a review of the literatureInt J Dermatol2009481190119420064173
   PubMed Web of Science ®Google Scholar
• CascavillaNBiscegliaMD’ArenaGSuccessful treatment of Schnitzler’s syndrome with anakinra after failure of rituximab trialInt J Immunopathol Pharmacol20102363363620646359
   PubMed Web of Science ®Google Scholar
• BesadaENossentHDramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler’s syndrome: a case report and literature reviewClin Rheumatol20102956757120119842
   PubMed Web of Science ®Google Scholar
• DellucALimalNPuéchalXFrancèsCPietteJCCacoubPEfficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndromeAnn Rheum Dis20086727827918192308
   PubMed Web of Science ®Google Scholar
• BotsiosCSfrisoPFurlanAPunziLDinarelloCAResistant Behçet disease responsive to anakinraAnn Intern Med2008149284286
   PubMed Web of Science ®Google Scholar
• BrennerMRuzickaTPlewigGThomasPHerzerPTargeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinraBr J Dermatol20091611199120119673875
   PubMed Web of Science ®Google Scholar
• WendlingDGovindarajuSPratiCToussirotEBertoliniEEfficacy of anakinra in a patient with refractory relapsing polychondritisJoint Bone Spine20087562262418674946
   PubMed Web of Science ®Google Scholar
• PiccoPBriscaGTraversoFLoyAGattornoMMartiniASuccessful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?Arthritis Rheum20096026426819116906
   PubMed Web of Science ®Google Scholar
• MartinonFPetrilliVMayorATardivelATschoppJGout-associated uric acid crystals activate the NALP3 inflammasomeNature200644023724116407889
   PubMed Web of Science ®Google Scholar
• NeogiTInterleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?Arthritis Rheum2010622845284920597109
   PubMed Web of Science ®Google Scholar
• SchumacherRHSundyJSTerkeltaubRPlacebo-controlled study of rilonacept for prevention of gout flares during initiation of urate-lowering therapyAnn Rheum Dis200968Suppl 368018511547
   PubMed Web of Science ®Google Scholar
• TerkeltaubRSundyJSSchumacherHRThe interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnn Rheum Dis2009681613161719635719
   PubMed Web of Science ®Google Scholar
• SoAde MeulemeesterMPikhlakACanakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging studyArthritis Rheum2010623064307620533546
   PubMed Web of Science ®Google Scholar
• SchlesingerNLinHYde MeulemeesterMEfficacy of canakinumab (ACZ885) in the prevention of flares in gout patients initiating allopurinol therapyAnn Rheum Dis201069Suppl 3121
   Google Scholar
• McGonagleDTanALMaddenJEmeryPMcDermottMFSuccessful treatment of resistant pseudogout with anakinraArthritis Rheum20085863163318240249
   PubMed Web of Science ®Google Scholar
• AnnounNPalmerGGuernePAGabayCAnakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failureJoint Bone Spine20097642442619289295
   PubMed Web of Science ®Google Scholar
• MitroulisISkendrosPRitisKTargeting IL-1beta in disease; the expanding role of NLRP3 inflammasomeEur J Intern Med20102157163
   Web of Science ®Google Scholar